• Exchange: Frankfurt
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharma

Clinuvel Pharmaceuticals Ltd

+ Add to Watchlist

UR9:GR

2.989 EUR 0.077 2.64%

As of 15:30:00 ET on 12/23/2014.

Snapshot for Clinuvel Pharmaceuticals Ltd (UR9)

Open: 2.896 Day's Range: 2.812 - 2.989 Volume: 450
Previous Close: 2.912 52wk Range: 0.570 - 3.517 1-Yr Rtn: +355.64%

Stock Chart for UR9

No chart data available.
  • UR9:GR 2.989
  • 1D
  • 1M
  • 1Y
2.912
Interactive UR9 Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for UR9

Current P/E Ratio (ttm) -
Estimated P/E(06/2015) -
Relative P/E vs. DAX -
Earnings Per Share (AUD) (ttm) -
Est. EPS (AUD) (06/2015) -
Est. PEG Ratio -
Market Cap (M EUR) 127.11
Shares Outstanding (M) 42.53
30 Day Average Volume 5,933
Price/Book (mrq) -
Price/Sale (ttm) -
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 02/26/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for UR9

  • Revenue
  • Net Income (M/AUD)
  • Profit Margin (%)

Company Profile & Key Executives for UR9

Clinuvel Pharmaceuticals Limited is an Australian biopharmaceutical company. The company focused on developing dermatology pharmaceutical products for a range of UV-related skin disorders. Clinuvel's work aims at preventing the symptoms of diseases related to harmful UV radiation.

Philippe J WolgenManaging Director/CEODarren M KeamyCFO/Secretary
Dennis J WrightActing Chief Scientific OfcrDavina GunnMgr:Investor Rels & Marketing
More Company Profile & Key Executives for UR9

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil